All IFN-omega reagents are produced in house and quality controlled, including 3 IFN-omega Antibody, 13 IFN-omega Gene, 2 IFN-omega Lysate, 2 IFN-omega Protein, 1 IFN-omega qPCR. All IFN-omega reagents are ready to use.
Recombinant IFN-omega proteins are expressed by HEK293 Cells with fusion tags as N-human IgG1-Fc, C-His.
IFN-omegaantibodies are validated with different applications, which are ELISA.
IFN-omegacDNA clones are full length sequence confirmed and expression validated. There are 13 kinds of tags for each IFN-omega of different species, especially GFP tag, OFP tag, FLAG tag and so on. There are three kinds of vectors for choice, cloning vector, expression vector and lentivrial expression vector.
IFNs are a large family of proteins having antiviral, antiproliferative, and immunomodulatory effects, and are divided into two major classes, type I and type I I, on the basis of differences in receptor binding and nucleotide sequence. Type I IFNs consist of IFN α, β, τ, and ω and bind to the type I IFN receptor, whereas IFN-γ is the only type I I IFN and is specific for the type I I IFN receptor. Human IFN-ω, was identified by three independent groups in 1985 and is structurally related to IFN-α and -β. Both human IFN-ω and IFN-α are produced by virally induced leukocytes and have similar antiviral activities on human cell lines, and a sizeable proportion (at least 10%) of the total antiviral activity of leukocyte IFN is contributed by IFN-ωl. In addition, it was reported that IFN-ω could inhibit the growth of human tumors in vivo.